AIM ImmunoTech Enters Material Agreement, Creates Financial Obligation
Ticker: AIM · Form: 8-K · Filed: Feb 20, 2024 · CIK: 946644
| Field | Detail |
|---|---|
| Company | Aim Immunotech INC. (AIM) |
| Form Type | 8-K |
| Filed Date | Feb 20, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $3,301,250, $781,250, $20,000, $2,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, debt, financial-obligation
TL;DR
**AIM ImmunoTech just took on a new financial obligation via a material agreement, watch for details!**
AI Summary
AIM ImmunoTech Inc. entered into a Material Definitive Agreement on February 16, 2024, which also created a Direct Financial Obligation for the company. The filing, dated February 20, 2024, details these events under Items 1.01 and 2.03 of Form 8-K. The company, based in Ocala, FL, operates in the biological products industry.
Why It Matters
This filing indicates a significant new commitment for AIM ImmunoTech, potentially impacting its financial health and future operations through a new obligation.
Risk Assessment
Risk Level: medium — The creation of a direct financial obligation introduces new liabilities and potential risks to the company's balance sheet.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- February 16, 2024 (date) — Date of Report/Agreement
- Ocala, FL (location) — Company headquarters
- 001-27072 (other) — Commission File Number
- 52-0845822 (other) — I.R.S. Employer Identification No.
FAQ
What is the purpose of this 8-K filing by AIM ImmunoTech Inc.?
This 8-K filing reports the entry into a Material Definitive Agreement and the creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, as per Items 1.01 and 2.03, respectively.
When did the reported events in this 8-K filing occur?
The reported events, specifically the entry into the Material Definitive Agreement, occurred on February 16, 2024.
What is the full legal name and location of the registrant?
The exact name of the registrant is AIM IMMUNOTECH INC., and its principal executive offices are located at 2117 SW Highway 484, Ocala, FL 34473.
What is the registrant's Commission File Number?
The registrant's Commission File Number is 001-27072.
What type of industry does AIM ImmunoTech Inc. operate in, according to its SIC code?
AIM ImmunoTech Inc. operates in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) industry, as indicated by its Standard Industrial Classification (SIC) code 2836.
Filing Stats: 1,042 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2024-02-20 16:31:03
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
- $3,301,250 — ") with an original principal amount of $3,301,250 in a private placement (the "Private Pl
- $781,250 — arries an original issuance discount of $781,250 and the Company agreed to pay $20,000 t
- $20,000 — $781,250 and the Company agreed to pay $20,000 to the Investor to cover the Investor's
- $2,500,000 — rchase price received by the Company of $2,500,000. The Note bears interest at ten perce
- $250,000 — to redeem any amount of the Note up to $250,000 (such amount, the "Monthly Redemption A
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex10-1.htm (EX-10.1) — 16KB
- ex10-2.htm (EX-10.2) — 5KB
- ex10-1_001.jpg (GRAPHIC) — 322KB
- ex10-1_002.jpg (GRAPHIC) — 475KB
- ex10-1_003.jpg (GRAPHIC) — 479KB
- ex10-1_004.jpg (GRAPHIC) — 388KB
- ex10-1_005.jpg (GRAPHIC) — 442KB
- ex10-1_006.jpg (GRAPHIC) — 411KB
- ex10-1_007.jpg (GRAPHIC) — 261KB
- ex10-1_008.jpg (GRAPHIC) — 393KB
- ex10-1_009.jpg (GRAPHIC) — 146KB
- ex10-1_010.jpg (GRAPHIC) — 77KB
- ex10-1_011.jpg (GRAPHIC) — 422KB
- ex10-1_012.jpg (GRAPHIC) — 413KB
- ex10-1_013.jpg (GRAPHIC) — 457KB
- ex10-1_014.jpg (GRAPHIC) — 468KB
- ex10-1_015.jpg (GRAPHIC) — 395KB
- ex10-1_016.jpg (GRAPHIC) — 458KB
- ex10-1_017.jpg (GRAPHIC) — 325KB
- ex10-2_001.jpg (GRAPHIC) — 362KB
- ex10-2_002.jpg (GRAPHIC) — 411KB
- ex10-2_003.jpg (GRAPHIC) — 368KB
- ex10-2_004.jpg (GRAPHIC) — 120KB
- ex10-2_005.jpg (GRAPHIC) — 57KB
- ex10-2_006.jpg (GRAPHIC) — 384KB
- ex10-2_007.jpg (GRAPHIC) — 20KB
- 0001493152-24-007230.txt ( ) — 11331KB
- aim-20240216.xsd (EX-101.SCH) — 3KB
- aim-20240216_lab.xml (EX-101.LAB) — 33KB
- aim-20240216_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM IMMUNOTECH INC. February 20, 2024 By: /s/ Thomas K. Equels Thomas K. Equels, CEO